Amgen Inc. (AMGN.O): Additional Dazo Sjogren's data highlight a competitive profile

AMGN released additional details from the OASIZ-301 Ph3 trial of dazodalibep (Dazo; CD40L) in Sjogren's disease (SD) with moderate-to-severe systemic activity, ahead of a presentation at ACR on 11/11, showing placebo-adjusted ESSDAI (primary endpoint) improvement of -1.8 and -1.4 at Week 48 for Q4W and Q12W dosing, respectively. Both Dazo doses of 1500mg IV Q4W and 3000mg IV Q12W met the primary endpoint of change in ESSDAI at week 48, with treatment effects observed as early as four weeks. Disease activity scores improved by a least-squares mean change from baseline of -5.6 points in patients receiving Dazo Q4W (difference vs. placebo, -1.8; adjusted p<0.001) and -5.2 points in those receiving Dazo Q12W (difference vs. placebo, -1.4; adjusted p=0.010), compared with -3.8 points for placebo;